C-Cube 3, building a more complete clinical proof by Pixience

Pixience au stand 21, congrès IFSCC.
Pixience au stand 21, congrès IFSCC.

In a context where scientific validation and marketing promotion converge, brands need tools capable of meeting multiple requirements: data rigour, visual richness, adaptability. It is at this junction that the C-Cube 3 is positioned, a hybrid solution that embodies the ideal frontier between the accuracy of measurement probes and the illustrative strength of clinical imagers.

Deux femmes illustrant la technologie Pixience C-Cube 3.

Designed for demanding research environments, the C-Cube is colorimetrically and metrically calibrated, ensuring reproducible measurements, even in varying light conditions. Without the need for a black part or complex adjustments, it facilitates the capture of standardized images in complete autonomy – a major advantage in a multi-center context.

Thanks to a single compact device, the teams have access to a wide range of quantitative parameters: pigmentation, erythema, texture, roughness, sebum, keratin, etc. These analyses are carried out on all areas of the body, and on all phototypes.

The C-Cube also incorporates 3D stereophotometry technology, allowing analysis of the skin surface in accordance with ISO 25178 (Sa, Sq, Sdr, Sz, Sp, Sv, Ssk, Sku). This measurement of the cutaneous topography opens the way to a fine objectification of the microrelief.

In short, by offering a hybrid approach, the C-Cube is the central link in a complete fleet of analysis systems. With a margin of error of less than 0.1%, it combines scientific reliability and analytical richness. Precise, versatile, and intuitive, it is a strategic ally for brands, CROs and laboratories, from R&D to final communication.

Advertorial


CONTACT

Sébastien Mangeruca
CEO

sales@pixience.com

https://www.pixience.com/en/c-cube-cr/

Logo Pixience, solutions technologiques en santé.

Discover their testing services during the exclusive webinar and the latest evaluation trends and innovations in preclinical trials and clinical studies.

moc.ecneixipskinobs_obfuscate@selas